The current market for CNS conditions is simultaneously one of the largest and yet among the least well served. Major pharmaceutical companies have been cutting back on neuroscience research and development, due to the high costs and the low historical probability of success. Yet, as our fundamental understanding of the brain is growing, there is hope for novel findings, potentially with translational implications. The Neurological Diseases session on May 23 will highlight some prime examples of the new approaches and discoveries, focusing on neurodegenerative diseases, such as Alzheimer’s disease, which remain among the biggest challenges to the medical system, while providing an enormous opportunity for those who invent solutions, and the patients who benefit from them.
FIND OUT MORE NEWS RELATED TO THE EVENT HERE OR SING UP INTO THE GROUP
